Cannabidiol, Morphine, Pain
Unknown statusPhase 1NCT04030442
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of the proposed study is to investigate the interaction of cannabidiol (CBD) and morphine effects on pain sensitivity. Cannabidiol is a cannabinoid (similar to cannabis, or marijuana) present in marijuana that alters some of the effects of marijuana.
Study details
- Official title
- Human Laboratory Model to Screen Drugs With Opioid Analgesic-sparing Effects: Cannabidiol/Morphine Combinations
- Conditions
- CBD
- Chronic Pain
- Interventions
- Drug: Immediate-release Oral Morphine Sulfate Tablets
- Other: Thermal and Pressure Nociceptive Sensitivity
- Sponsor
- Wayne State University
- Start date
- 2019-05-01
- Primary completion
- 2025-01-26
- Sex
- All
- Age range
- from 18 Years to 55 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Participants must report having smoked a cigarette (nicotine or marijuana) AND having taken an opioid on 3 or more occasions in their lifetime. * Participants must be in good health to participate; those with certain contraindications will be excluded. * All participants will undergo psychiatric evaluation and will be asked to report their substance use history by interview and structured questionnaire methods. * Participants will undergo medical evaluations using medical history, physical exam, standard lab tests (complete blood chemistry, urinalysis, urine pregnancy test for females), and 12-lead ECG. Exclusion Criteria: * Serious psychiatric illness (e.g. psychotic or bipolar disorder, recent suicide attempts; severe depression) * Substance Use Disorders other than Nicotine Use Disorder and Mild Cannabis Use Disorder * Neurological diseases; cardiovascular problems (e.g. systolic BP \>140 or \<95 mmHg, diastolic BP \>90 mmHg, abnormal ECG); pulmonary diseases; systemic diseases (e.g. liver, renal, inflammatory) * Cognitive impairment (\<80 IQ) * Past-month medications that increase study risk * Women who are pregnant (urine HCG), lactating (self-report), or if heterosexually active and not using (self-report) medically approved birth control (oral or depot contraception, IUD, condom/foam, sterilization, tubal ligation) * Individuals unable to give informed consent will be excluded.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04030442